

# Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

<https://marketpublishers.com/r/GC6B618F60FEN.html>

Date: September 2020

Pages: 163

Price: US\$ 5,500.00 (Single User License)

ID: GC6B618F60FEN

## Abstracts

### Report Scope:

This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement, and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2019 and forecast for 2020-2025 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.

The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV, and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions, and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics, and others, are detailed with market data current and forecasts.

Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America, and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States,

Europe, Japan, and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to our readers.

#### Report Includes:

33 data tables and 42 additional tables

An overview of the global markets for treatment and diagnosis of sexually transmitted diseases

Analyses of the global market trends, with corresponding market analysis data for 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025

Evaluation of the impact of demographic, economic and other factors that will drive future demand for diagnostic and therapeutic interventions affecting sexually transmitted diseases market

Estimation of market size and forecast the potential market for sexually transmitted disease therapeutics, along with global market share analysis on the basis of disease area and treatments, drug type, and geographical region

Identification of unmet needs in sexually transmitted diseases therapeutics, promising new drugs and therapies still in the development and testing stage that will be commercialized successfully in the next five years

Assessment of the long-term outlook for sexually transmitted diseases therapeutics, considering market opportunities as well as technological, financial and economic factors

Insight into the factors driving and restraining the growth of the global market for treatment and diagnosis of sexually transmitted diseases, along with a regional market overviews for North America, Europe, Asia-Pacific, Latin America and the Middle East

Company profiles of the leading drug manufacturers and suppliers, market including Abbott Laboratories, AbbVie Inc., Novartis AG, Pfizer Inc., and Thermo Fisher Scientific Inc.



## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
BCC Custom Research  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 GLOBAL MARKET OVERVIEW AND TRENDS**

Overview of Sexually Transmitted Diseases and Definitions  
Sexually Transmitted Diseases and Pregnancy  
Screening Programs and Guidelines  
Mobile HIV Testing in Brazil  
Benzathine Penicillin Drug Shortage  
Trends in the Global Transmission of STDs  
Increasing Incidence of STDs  
STD Awareness and Screening Services  
Development of Test Kits with High Sensitivity for Low Resource Settings  
Challenges  
Underestimating the Risk of Contracting the Disease  
Social Stigma Associated with STDs  
Rising Incidence of Antibiotic Resistance  
Lack of Prenatal Screening for STDs

### **CHAPTER 4 DISEASE OVERVIEW**

Introduction  
Chlamydia  
Overview  
Epidemiology

Diagnosis  
Treatments  
Genital Herpes  
Overview  
Epidemiology  
Diagnosis  
Treatments  
Gonorrhea  
Overview  
Epidemiology  
Treatments  
Hepatitis A, B and C  
Overview  
Epidemiology  
Diagnosis  
Treatments  
Market Size  
HIV/AIDS  
Overview  
Epidemiology  
Diagnosis  
Treatments  
Market Size and Forecast  
HPV  
Overview  
Diagnosis  
Treatments  
Syphilis  
Overview  
Epidemiology  
Diagnosis  
Treatments  
Others  
Overview  
Market Analysis

## **CHAPTER 5 STD DIAGNOSIS AND TREATMENT OPTIONS**

Introduction to STD Diagnostics by Test Type

Enzyme Immunoassay (EIA) and ELISA  
Polymerase Chain Reaction (PCR)  
Rapid Diagnostics Tests (RDTs)  
Others  
Introduction to Treatment by Drug Class  
Antibiotics/Antibacterial  
Antiviral/ Antiretrovirals  
Others

## **CHAPTER 6 NORTH AMERICAN MARKET**

North American Market  
United States  
Canada  
Mexico

## **CHAPTER 7 EUROPEAN MARKET**

European Market  
United Kingdom  
Germany  
France  
Spain  
Italy  
Rest of Europe

## **CHAPTER 8 ASIA-PACIFIC MARKET**

Introduction  
Key Trends in STI Prevention  
Asia-Pacific Market  
China  
Japan  
India  
South Korea  
Rest of Asia-Pacific

## **CHAPTER 9 REST OF THE WORLD MARKET**

Rest of the World Market

## **CHAPTER 10 REGULATORY STRUCTURE**

Overview of Regulations

United States

Europe

Japan

China

Overview of Pricing and Reimbursement

United States

Europe

Japan

## **CHAPTER 11 COMPANY PROFILES**

ABBOTT LABORATORIES

ABBVIE INC.

AGILENT TECHNOLOGIES INC.

BECTON, DICKINSON AND CO.

BIOMERIEUX INC.

BIO-RAD LABORATORIES INC.

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

BRISTOL-MYERS SQUIBB CO.

CEPHEID INC.

GILEAD SCIENCES INC.

GLAXOSMITHKLINE PLC

HOFFMANN-LA ROCHE INC.

HOLOGIC INC.

MERCK & CO. INC.

NOVARTIS AG

PFIZER INC.

PROMEGA CORP.

QIAGEN N.V.

QUIDEL CORP.

THERMO FISHER SCIENTIFIC INC.

## **CHAPTER 12 APPENDIX**

## Acronyms



## List Of Tables

### LIST OF TABLES

Table A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2025

Table B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2025

Table 1: Sexually Transmitted Diseases, by Different Pathogens

Table 2: Global Market for STD Therapeutics, by Disease Area, Through 2025

Table 3: Incidence of Chlamydia, by Country, 2012-2018

Table 4: Chlamydia Diagnostic Products, by Brand Name and Manufacturer

Table 5: Drugs for Chlamydia Treatment

Table 6: Global HSV-1 Prevalence Cases, Aged 0-49 years, by Region, 2016

Table 7: Global HSV-1 Prevalence, Aged 0-49 years, by Region, 2016

Table 8: Genital Herpes Diagnostic Products, by Brand Name and Manufacturer

Table 9: Epidemiology of Gonorrhea, by Country, 2012-2018

Table 10: Gonorrhea Diagnostic Products, by Brand Name and Manufacturer

Table 11: Drug for Gonorrhea Treatment

Table 12: Incidence of Hepatitis A, by Country, 2012-2017

Table 13: Incidence of Hepatitis B, by Country, 2012-2017

Table 14: Incidence of Hepatitis C, by Country, 2012-2015

Table 15: Hepatitis B and C Diagnostic Products, by Brand Name and Manufacturer

Table 16: Hepatitis B Medications, by Brand Name, Generic Name, Manufacturer, and Indication

Table 17: Hepatitis C Medications, by Brand Name, Generic Name, Manufacturer, and Indication

Table 18: Global Market for Hepatitis Therapeutics, by Region, Through 2025

Table 19: HIV Prognosis

Table 20: Snapshot of Global HIV Epidemic, by Region, 2019

Table 21: HIV/AIDS Diagnostic Products, by Brand Name and Manufacturer

Table 22: HIV Medications, by Drug Class, Generic Name, and Brand Name

Table 23: Global Market for HIV/AIDS Therapeutics, by Region, Through 2025

Table 24: HPV Diagnostic Products, by Brand Name and Manufacturer

Table 25: HPV Vaccines

Table 26: Incidence of Syphilis, by Country, 2013-2018

Table 27: Syphilis Diagnostic Products, by Brand Name and Manufacturer

Table 28: Drug for Syphilis Treatment

Table 29: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type, and

**Manufacturer**

Table 30: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer

Table 31: Global Market for Other Therapeutics, by Region, Through 2025

Table 32: Global Market for STD Diagnostics, by Region, Through 2025

Table 33: Global Market for STD Diagnostics, by Test Type, Through 2025

Table 34: Antibacterial Drugs for Treatment of STDs

Table 35: Global Market for Antibiotics, by Region, Through 2025

Table 36: Global Market for Antiviral/Antiretroviral Drugs, by Region, Through 2025

Table 37: Global Market for Other Drug Classes, by Region, Through 2025

Table 38: North American HBsAG Seroprevalence, by Country, 2016

Table 39: North American Market for STD Therapeutics, by Disease Area, Through 2025

Table 40: North American Market for STD Therapeutics, by Drug Class, Through 2025

Table 41: U.S. Historic and Current Chancroid Trends and Incidence, 1990-2018

Table 42: European Market for STD Therapeutics, by Disease Area, Through 2025

Table 43: European Market for STD Therapeutics, by Drug Class, Through 2025

Table 44: Asia-Pacific Market for STD Therapeutics, by Disease Area, Through 2025

Table 45: Asia-Pacific Market for STD Therapeutics, by Drug Class, Through 2025

Table 46: South American, Middle Eastern and African HIV/AIDS Epidemiology, 2019

Table 47: South American, Middle Eastern and African Market for STD Therapeutics, by Disease Area, Through 2025

Table 48: South American, Middle Eastern and African Market for STD Therapeutics, by Drug Class, Through 2025

Table 49: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing

Table 50: Preventive Health Services for Children Covered by Private Plans without Cost Sharing

Table 51: Abbott Laboratories: Marketed Products

Table 52: Abbott Laboratories: Marketed Products, Diagnostics

Table 53: Abbott Laboratories: Financials, 2017-2019

Table 54: AbbVie Inc.: Marketed Products

Table 55: AbbVie Inc.: Financials, 2017-2019

Table 56: Agilent Technologies Inc.: Financials, 2017-2019

Table 57: Becton, Dickinson and Co.: Marketed Products

Table 58: Biomerieux Inc.: Marketed Products

Table 59: Bio-Rad Laboratories: Marketed Products

Table 60: Bristol-Myers Squibb Co.: Marketed Products

Table 61: Bristol-Myers Squibb Company: Financials, 2017-2019

Table 62: Gilead Sciences Inc.: Marketed Products

- Table 63: GlaxoSmithKline plc: Marketed Products
- Table 64: ViiV Healthcare Group of Companies: Marketed Products
- Table 65: Hoffmann-La Roche Inc.: Marketed Products
- Table 66: Hologic Inc.: Marketed Products
- Table 67: Hologic Inc.: Financials, 2017-2019
- Table 68: Merck & Co. Inc.: Marketed Products
- Table 69: Novartis AG: Marketed Products
- Table 70: Pfizer Inc.: Marketed Products, by Indication
- Table 71: Qiagen N.V.: Marketed Products
- Table 72: Quidel Corp.: Marketed Products
- Table 73: Thermo Fisher Scientific Inc.: Marketed Products
- Table 74: Acronyms Used in the Sexually Transmitted Disease Therapeutics and Diagnostics Market

## List Of Figures

### LIST OF FIGURES

Figure A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2019-2025

Figure B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2019-2025

Figure 1: Death Share Due to Infectious and Parasitic Diseases, 2016

Figure 2: Incidence of Gonorrhoea, by Country, 2015-2018

Figure 3: U.S. Funding Trends, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2019

Figure 4: Global Market for STD Therapeutics, 2019-2025

Figure 5: Global Market Shares of STD Therapeutics, by Disease Area, 2019

Figure 6: Global Market Shares of STD Therapeutics, by Disease Area, 2025

Figure 7: Global Historic and Current Chlamydia Trend and Incidence in Women, by Country, 2016-2018

Figure 8: Global Incidence of Gonorrhoea in Men, by Country, 2015-2017

Figure 9: Hepatitis Timeline, 1990-2004

Figure 10: Hepatitis Timeline, 2011-2015

Figure 11: Hepatitis Timeline, 2015-2017

Figure 12: Global Market for Hepatitis Therapeutics, 2019-2025

Figure 13: Global Market for Hepatitis Therapeutics, by Region, 2019-2025

Figure 14: Global Market for HIV/AIDS Therapeutics, 2019-2025

Figure 15: Global Market for HIV/AIDS Therapeutics, by Region, 2019-2025

Figure 16: U.S. Incidence of Syphilis Among Newborns, 2016-2018

Figure 17: Global Market for Other Therapeutics, 2019-2025

Figure 18: Global Market for Other Therapeutics, by Region, 2019-2025

Figure 19: Global Market for STD Diagnostics, 2019-2025

Figure 20: Global Market for STD Diagnostics, by Region, 2019-2025

Figure 21: Global Market Shares of STD Diagnostics, by Test Type, 2019

Figure 22: Global Market Shares of STD Diagnostics, by Test Type, 2025

Figure 23: Global Market for EIA and ELISA Diagnostics, 2019-2025

Figure 24: Global Market for PCR Diagnostics, 2019-2025

Figure 25: Global Market for RDT Diagnostics, 2019-2025

Figure 26: Global Market for Other Diagnostics, 2019-2025

Figure 27: Global Market for Antibiotic Drugs, 2019-2025

Figure 28: Global Market for Antibiotic Drugs, by Region, 2019-2025

Figure 29: Global Market for Antiviral/Antiretroviral Drugs, 2019-2025

Figure 30: Global Market for Antiviral/Antiretroviral Drugs, by Region, 2019-2025

- Figure 31: Global Market for Other Drug Classes, 2019-2025
- Figure 32: Global Market for Other Drug Classes, by Region, 2019-2025
- Figure 33: North American Market for STD Therapeutics, 2019-2025
- Figure 34: North American Market Shares of STD Therapeutics, by Disease Area, 2019
- Figure 35: North American Market Shares of STD Therapeutics, by Disease Area, 2025
- Figure 36: North American Market Shares of STD Therapeutics, by Drug Class, 2019
- Figure 37: North American Market Shares of STD Therapeutics, by Drug Class, 2025
- Figure 38: North American Market for STD Therapeutics, by Country, 2019-2025
- Figure 39: U.S. Incidence of STDs, 2018
- Figure 40: U.S. Sexually Transmitted Infections, by Sex, 2018
- Figure 41: U.S. Historic and Current Syphilis Trends and Incidence, 2000-2018
- Figure 42: U.S. Historic and Current Chlamydia Trends and Incidence, 2000-2018
- Figure 43: U.S. Historic and Current Gonorrhea Trends and Incidence, 2000-2018
- Figure 44: U.S. Historic and Current Hepatitis A Trends and Incidence, 2013-2018
- Figure 45: U.S. Historic and Current Acute Hepatitis B Trends and Incidence, 2013-2018
- Figure 46: U.S. Historic and Current Hepatitis C Trends and Incidence, 2013-2018
- Figure 47: U.S. Historic and Current HIV Trends and Incidence, 2011-2018
- Figure 48: U.S. Market for STD Therapeutics, 2019-2025
- Figure 49: Canadian Sexually Transmitted Infections, by Sex, 2018
- Figure 50: Canadian Historic and Current Chlamydia Trends and Incidence, 2008-2018
- Figure 51: Canadian Historic and Current Gonorrhea Trends and Incidence, by Sex, 2008-2018
- Figure 52: Canadian Historic and Current Infectious Syphilis Trends and Incidence, 2008-2018
- Figure 53: Canadian Historic and Current Congenital Syphilis Trends and Incidence, 2008-2018
- Figure 54: Canadian Market for STD Therapeutics, 2019-2025
- Figure 55: Mexican Market for STD Therapeutics, 2019-2025
- Figure 56: European Historic and Current Chlamydia Trends and Incidence, by Country, 2014-2018
- Figure 57: European Historic and Current AIDS Trends and Incidence, by Country, 2014-2018
- Figure 58: European Market for STD Therapeutics, 2019-2025
- Figure 59: European Market Shares of STD Therapeutics, by Disease Area, 2019
- Figure 60: European Market Shares of STD Therapeutics, by Disease Area, 2025
- Figure 61: European Market Shares of STD Therapeutics, by Drug Class, 2019
- Figure 62: European Market Shares of STD Therapeutics, by Drug Class, 2025
- Figure 63: European Market for STD Therapeutics, by Country, 2019-2025

- Figure 64: U.K. Incidence of HIV among Gay and Bisexual Men, 2015-2018
- Figure 65: U.K. Historic and Current Gonorrhoea Trends and Incidence, 2014-2018
- Figure 66: U.K. Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 67: U.K. Historic and Current Hepatitis C Trends and Incidence, 2012-2018
- Figure 68: U.K. Market for STD Therapeutics, 2019-2025
- Figure 69: German Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 70: German Historic and Current Hepatitis C Trends and Incidence, 2012-2018
- Figure 71: German Market for STD Therapeutics, 2019-2025
- Figure 72: French Historic and Current Chlamydia Trends and Incidence, 2012-2017
- Figure 73: French Historic and Current Gonorrhoea Trends and Incidence, 2014-2018
- Figure 74: French Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 75: French Market for STD Therapeutics, 2019-2025
- Figure 76: Spanish Historic and Current Chlamydia Trends and Incidence, 2012-2018
- Figure 77: Spanish Historic and Current Gonorrhoea Trends and Incidence, 2012-2018
- Figure 78: European Centre for Disease Prevention and Control: Annual Epidemiological Report
- Figure 79: Spanish Market for STD Therapeutics, 2019-2025
- Figure 80: Italian Historic and Current Chlamydia Trends and Incidence, 2012-2018
- Figure 81: Italian Historic and Current Gonorrhoea Trends and Incidence, 2011-2018
- Figure 82: Italian Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 83: Italian Historic and Current Hepatitis C Trends and Incidence, 2012-2018
- Figure 84: Italian Market for STD Therapeutics, 2019-2025
- Figure 85: Denmark's Historic and Current Chlamydia Trends and Incidence, 2012-2018
- Figure 86: The Netherlands Historic and Current Chlamydia Trends and Incidence, 2012-2018
- Figure 87: Denmark's Historic and Current Gonorrhoea Trends and Incidence, 2011-2018
- Figure 88: Irish Historic and Current Gonorrhoea Trends and Incidence, 2012-2018
- Figure 89: The Netherlands Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 90: Swedish Historic and Current Hepatitis B Trends and Incidence, 2012-2018
- Figure 91: Swedish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
- Figure 92: Polish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
- Figure 93: Rest of European Market for STD Therapeutics, 2019-2025
- Figure 94: Asia-Pacific Market for STD Therapeutics, 2019-2025
- Figure 95: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2019
- Figure 96: Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2025
- Figure 97: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2019

Figure 98: Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2025

Figure 99: Asia-Pacific Market for STD Therapeutics, by Country, 2019-2025

Figure 100: Chinese Market for STD Therapeutics, 2019-2025

Figure 101: Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2017

Figure 102: Japanese Market for STD Therapeutics, 2019-2025

Figure 103: Indian Historic and Current HIV Trends and Incidence, 2005-2018

Figure 104: Indian Historic and Current HIV Trends and Prevalence, 2005-2018

Figure 105: Indian Historic and Current AIDS Mortality, 2005-2018

Figure 106: Indian Market for STD Therapeutics, 2019-2025

Figure 107: South Korean Historic and Current HIV/AIDS Infections and Incidence, 2001-2018

Figure 108: South Korean Market for STD Therapeutics, 2019-2025

Figure 109: Rest of Asia-Pacific Market for STD Therapeutics, 2019-2025

Figure 110: South American, Middle Eastern and African Market for STD Therapeutics, 2019-2025

Figure 111: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Disease Area, 2025

Figure 112: South American, Middle Eastern and Africa Market Shares of STD Therapeutics, by Drug Class, 2019

Figure 113: South American, Middle Eastern and African Market Shares of STD Therapeutics, by Drug Class, 2025

Figure 114: Abbott Laboratories: Revenue Share, by Region, 2019

Figure 115: Abbott Laboratories: Revenue Share, by Business Segment, 2019

Figure 116: AbbVie Inc.: Revenue Share, by Country, 2019

Figure 117: Agilent Technologies Inc.: Revenue Share, by Region, 2019

Figure 118: Agilent Technologies Inc.: Revenue Share, by Business Segment, 2019

Figure 119: Becton, Dickinson and Co.: Financial Performance, 2013-2019

Figure 120: Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2019

Figure 121: Becton, Dickinson and Co.: Revenue Share, by Region, 2019

## I would like to order

Product name: Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

Product link: <https://marketpublishers.com/r/GC6B618F60FEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC6B618F60FEN.html>